FDA INTERACT Meetings: Early Strategic Alignment for Innovative Therapies
At Global Regulatory Partners (GRP), we understand that early regulatory strategy plays a critical role in the success of innovative drug development programs. For companies developing novel therapies—especially those with limited regulatory precedent—the FDA’s INTERACT meeting represents a valuable opportunity to engage with the Agency at a formative stage.
INTERACT (Initial Targeted Engagement for Regulatory Advice on CBER- and CDER-Regulated Products) is designed to support early, focused dialogue between sponsors and FDA reviewers. When strategically utilized, it helps identify potential risks, refine development strategies, and establish a solid regulatory foundation before significant investments are made.
The Future of Digital Health: ANVISA and the New Era of AI in Software as a Medical Device (SaMD)
This Blog details the revision of RDC No. 657/2022 by ANVISA, driven by the rise of Generative AI. We discuss how new risk classification criteria impact the development of software that diagnoses and suggests treatments, ensuring patient safety without stifling innovation.
Brazil and Mexico: A New Era of Sanitary Integration and Innovation in Latin America
This article explores the recent strengthening of bilateral cooperation between the regulatory agencies of Brazil and Mexico. The central focus is the harmonization of standards to accelerate the registration of medicines and medical devices, while fostering regional biotech innovation hubs.
Strengthening Innovation and Compliance Across Pharma, Medical China Regulatory and Cosmetics
China continues to advance its life sciences regulatory framework with a strong emphasis on balancing innovation and regulatory oversight. Recent updates issued by the National Medical Products Administration (NMPA) and the Center for Drug Evaluation (CDE) introduce new clinical evaluation guidance for pharmaceuticals and enhanced technical standards for cosmetic ingredients. These measures signal a continued shift toward life cycle-based regulation, scientific consistency, and higher quality standards across regulated products.
EMA Guidance on GMP Considerations for Additive Manufacturing of Solid Oral Dosage Forms
The European Medicines Agency (EMA) has issued guidance addressing Good Manufacturing Practice (GMP) considerations for the use of additive manufacturing, also known as 3D printing (3DP), in the production of solid oral dosage forms. This guidance represents a significant step toward integrating innovative manufacturing technologies into the pharmaceutical regulatory framework while ensuring product quality, safety, and efficacy.
LMR 2026 Update: How Normative Instruction No. 428 Impacts Pharmaceutical Competitiveness
On March, 2026, ANVISA published Normative Instruction (IN) No. 428, bringing crucial updates to the Reference Medicines List (LMR). This movement is vital for companies seeking to register generics and similar drugs, ensuring that bioequivalence and bioavailability studies use the correct comparator.
Global Pharmacovigilance: Mandatory Use of MedDRA and WHO Drug in the VigiMed System
Starting March,2026, ANVISA establishes a new milestone for pharmacovigilance in Brazil the mandatory use of the international dictionaries MedDRA and WHO Drug for all notifications within the VigiMed system. This change aims to integrate Brazilian data into the global health ecosystem, allowing for faster and more accurate risk analysis.
Mexico Strengthens Health Security: The Transition from the CNFV to the New CENAFyT
Mexico has taken a decisive step in modernizing its healthcare system with the creation of the National Center for Pharmacovigilance and Technovigilance (CENAFyT). Integrated into the General Health Law, this new body expands supervisory powers over both medicines and medical equipment, ensuring greater protection for all citizens.
The New period of Regulation in Mexico: Modernization and Sovereignty (2024–2026)
Between 2024 and 2026, Mexico underwent a profound transformation of its regulatory landscape for medicines and vaccines. Led by COFEPRIS, this shift focuses on agility through the “regulatory reliance” model, ensuring that medical innovation reaches patients faster without compromising scientific rigor or national sovereignty.
Regulatory Modernization in Brazil: ANVISA’s Path Toward Traceability and Agility in 2026
The Brazilian regulatory landscape in 2026 solidifies the transition to a fully digital environment. With the mandatory implementation of Unique Device Identification (UDI) and new rules for electronic prescriptions, ANVISA focuses on patient safety and the de-bureaucratization of processes.
Registration Hosting: Protecting Your Brand in Brazil
Entering the Brazilian market requires more than just a great product; it demands compliance with one of the world’s most rigorous regulatory agencies: ANVISA. This blog post explains how Registration Hosting serves as a strategic solution for foreign companies seeking agility, reduced operational costs, and legal protection for their brands in Brazil.
Mastering RDC 406/2020 – Good Pharmacovigilance Practices in Brazil
This blog post explores the critical guidelines established by RDC 406/2020, which regulates Good Pharmacovigilance Practices (GVP) for Marketing Authorization Holders (MAH) in Brazil. We will break down the responsibilities, the required organizational structure, and how compliance with these ANVISA standards ensures safety within the Brazilian pharmaceutical market.